Tech giant IBM (IBM) is trying to show that quantum computing is no longer just a science experiment. Interestingly, at its Think 2026 event, the company highlighted a quantum-assisted protein simulation that it said improved accuracy by 210 times. Indeed, the firm used these findings to show the potential real-world applications of the technology. According to IBM Research, the basic idea is that many things in nature, like molecules and materials, already follow quantum rules. So instead of forcing regular computers to imitate that behavior, IBM wants quantum and classical computers to work together.
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade IBMOne example came from the Cleveland Clinic and RIKEN, which used IBM’s quantum hardware to simulate a large protein complex made up of 12,635 atoms. In simple terms, they were studying how a molecule interacts with a protein, which can be important for drug discovery. IBM said that this was the largest protein-ligand simulation of its kind using quantum and classical computing together. Because the work improved accuracy by 210 times compared with earlier methods, IBM is using it as evidence that quantum computing may eventually help solve scientific problems that regular computers struggle with.
In addition, IBM pointed to progress in materials science through Q-CTRL, which used the IBM Quantum Platform to run a practical simulation much faster than a leading traditional method. The test involved up to 60 interacting electrons, which is difficult for many regular computing methods to handle. However, the quantum-based approach finished in about two minutes, compared with roughly 100 hours on classical hardware, while staying within 1% accuracy.
Is IBM a Buy, Sell, or Hold?
Turning to Wall Street, analysts have a Moderate Buy consensus rating on IBM stock based on 11 Buys, seven Holds, and zero Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average IBM price target of $292.63 per share implies 28.4% upside potential.
